Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Company Deals

HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones

Fineline Cube Dec 18, 2025
Company Deals

Sanofi Adel Alzheimer’s Deal Targets Phase 1 ADEL-Y01 Antibody

Fineline Cube Dec 18, 2025
Company Deals

Byterna Therapeutics Raises Angel Plus Round for cmRNA CAR‑T Pipeline

Fineline Cube Dec 17, 2025
Company Deals

Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal

Fineline Cube Dec 17, 2025
Policy / Regulatory

FDA Removes Key RWE Limitation, Allowing Drug and Device Submissions Without Individual Patient Data

Fineline Cube Dec 16, 2025
Company Drug

Hutchmed’s HMPL-A251 ATTC Dosed in Global Phase 1 for HER2 Tumors

Fineline Cube Dec 18, 2025
Company Drug

Antengene Xpovio sNDA Malaysia Approval Expands DLBCL Indication

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025

Xinyuan Zhenghe (Hangzhou) Private Equity Fund Management Co., Ltd., Sirnaomics, and the Fuyang Economic and...

Hospital

Hainan Opens First Wholly Foreign-Owned Hospital Ahead of Free Trade Port Launch

Fineline Cube Dec 18, 2025

Boao Fullerton Hospital, the first wholly foreign‑owned hospital in Hainan, held its unveiling ceremony today...

Company Drug

Hutchmed’s HMPL-A251 ATTC Dosed in Global Phase 1 for HER2 Tumors

Fineline Cube Dec 18, 2025

Chinese pharmaceutical company HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced the initiation of a...

Company Deals

HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones

Fineline Cube Dec 18, 2025

HBM Holdings Limited (HKG: 2142) announced it has entered into a long-term global strategic collaboration...

Company Drug

Antengene Xpovio sNDA Malaysia Approval Expands DLBCL Indication

Fineline Cube Dec 18, 2025

Antengene Corporation Limited (HKG: 6996) announced that the Malaysian National Pharmaceutical Regulatory Agency has approved...

Company Drug

Everest lerodalcibep PCSK9 FDA Approval Targets China Launch

Fineline Cube Dec 18, 2025

Everest Medicines Limited (HKG: 1952) announced that the U.S. FDA has approved the Biologics License...

Company Medical Device

Cryofocus GERD System Secures NMPA Approval in China

Fineline Cube Dec 18, 2025

Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922) announced that its Anti-Gastroesophageal Reflux System has been...

Company Deals

Sanofi Adel Alzheimer’s Deal Targets Phase 1 ADEL-Y01 Antibody

Fineline Cube Dec 18, 2025

Sanofi (NASDAQ: SNY) announced a license agreement with South Korean biotech Adel to gain exclusive...

Company Deals

Byterna Therapeutics Raises Angel Plus Round for cmRNA CAR‑T Pipeline

Fineline Cube Dec 17, 2025

Byterna Therapeutics completed its angel plus round financing, exclusively invested by Efung Capital. Proceeds will...

Company Drug

GSK’s Exdensur Wins FDA Approval as First Twice‑Yearly Asthma Biologic

Fineline Cube Dec 17, 2025

GlaxoSmithKline plc (GSK, NYSE: GSK) announced that the U.S. Food and Drug Administration (FDA) approved...

Hospital

Beijing Friendship Hospital Launches Cell and Gene Therapy Center for Liver Diseases

Fineline Cube Dec 17, 2025

The Cell and Gene Therapy Innovation and Transformation Center was officially established at Beijing Friendship...

Company Deals

Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal

Fineline Cube Dec 17, 2025

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced a settlement agreement with Medilink Therapeutics resolving...

Company Deals

Hansoh Licenses EGFR Drug Aumolertinib to Glenmark for $1B+ in Milestones

Fineline Cube Dec 17, 2025

Jiangsu Hansoh Pharmaceutical Co. Ltd. (HKG: 3692) entered into an exclusive license, collaboration, and distribution...

Company Deals

Fangzhou and Huilun Partner on AI-Driven Chronic Disease Management Platform

Fineline Cube Dec 17, 2025

Guangzhou-based smart healthcare service platform Fangzhou Inc. (HKG: 6086) and Shanghai Huilun Pharmaceutical Co., Ltd....

Company Drug

Adagene’s Muzastotug Wins FDA Fast Track for CTLA-4 Cancer Combo

Fineline Cube Dec 17, 2025

Adagene Inc. (NASDAQ: ADAG) announced that the U.S. Food and Drug Administration (FDA) granted Fast...

Company Drug

Aficamten Wins China Approval as HCM Drug in Global First for Sanofi

Fineline Cube Dec 17, 2025

Sanofi (NASDAQ: SNY) announced that aficamten, a second‑generation cardiac myosin inhibitor, received marketing approval from...

Company Drug

Haisco Wins NMPA Clinical Approval for Four Category 1 Drugs, Advancing Pipeline

Fineline Cube Dec 17, 2025

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared

Fineline Cube Dec 16, 2025

InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that its self‑developed novel BTK inhibitor orelabrutinib...

Company Deals

Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal

Fineline Cube Dec 16, 2025

Saizeng Medical Technology Co. Ltd, a subsidiary of Changchun High‑Tech Industry (Group) Co., Ltd. (SHE:...

Company Medical Device

Zhicheng’s TAVR Robotic System Enters NMPA Innovation Pathway

Fineline Cube Dec 16, 2025

Zhicheng Medical Technology (Jiaxing) Co., Ltd. announced that its self‑developed ReachTact Transcatheter Aortic Valve Replacement...

Posts pagination

1 2 … 599

Recent updates

  • Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou
  • Hainan Opens First Wholly Foreign-Owned Hospital Ahead of Free Trade Port Launch
  • Hutchmed’s HMPL-A251 ATTC Dosed in Global Phase 1 for HER2 Tumors
  • HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones
  • Antengene Xpovio sNDA Malaysia Approval Expands DLBCL Indication
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Hospital

Hainan Opens First Wholly Foreign-Owned Hospital Ahead of Free Trade Port Launch

Company Drug

Hutchmed’s HMPL-A251 ATTC Dosed in Global Phase 1 for HER2 Tumors

Company Deals

HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.